A long term partnership

Introduced in 1985 as a spin-off of the University of Liege (BE), Eurogentec became a member of the international Japanese chemical company – Kaneka Corporation in 2010.

Ever since, the company has developed proprietary processes and continues to expand its investments to offer cutting-edge products to scientists around the world.

Eurogentec is founded as a spin-off of
the University of Liege (Belgium, EU)

We started the production of  Oligonucleotides
for Research laboratories

GMP Production facility is accredited
by Belgian Health Authorities

Eurogentec began its custom antibody development service

We started the synthesis of custom peptides

We became a contract research organization (CRO) for the biopharmaceutical sector

We started to manufacture and sell kits
for qPCR application

New production laboratories (Oligonucleotides and peptides synthesis) are inaugurated in the Liege Science Park (Belgium)

We received our first ISO 13485 certification for the production and sales of In Vitro Diagnostics (IVD) oligonucleotides in Liege

AnaSpec has become a subsidiary of Eurogentec

Founded in 1993, AnaSpec a privately owned proteomics company based in Fremont - USA is recognized as a leading provider of integrated proteomics solutions. The company has expertise in peptides synthesis, labeled peptides and antibodies, fluorescent dyes and enzyme activity assays

Eurogentec joined Kaneka Corporation an innovation-oriented chemical company headquartered in Osaka

We celebrated the inauguration of our new facility extension dedicated to the quality control and the stock of raw materials for the production of biopharmaceuticals

We laid the first stone for a new large scale pharmaceutical grade biologics manufacturing facility

We launched the Therapeutic grade oligonucleotides, IVT RNA and CRM peptides

Our new GMP BioPharmaceutical facility is ready

Our 2200L fermenter will allow the GMP production of kg-scale plasmid DNA and recombinant proteins for use in human clinical trials and commercialization

  • 1985
  • 1987
  • 1994
  • 1995
  • 1996
  • 2001
  • 2004
  • 2008
  • 2009
  • 2010
  • 2016
  • 2018
  • 2019

Our current and future ambition is to stay among the top-5 leading providers of Life Sciences Solutions. To achieve this goal, we develop new technologies, invest in state of the art equipment and continuously surround ourselves with new talents.”

Lieven JANSSENS - President

Be a part of
our story

Working at Eurogentec is participating to enchance the life science research and modern medicine.

Our job opportunities